[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA02002483A - Vacuna contra vhb y vph. - Google Patents

Vacuna contra vhb y vph.

Info

Publication number
MXPA02002483A
MXPA02002483A MXPA02002483A MXPA02002483A MXPA02002483A MX PA02002483 A MXPA02002483 A MX PA02002483A MX PA02002483 A MXPA02002483 A MX PA02002483A MX PA02002483 A MXPA02002483 A MX PA02002483A MX PA02002483 A MXPA02002483 A MX PA02002483A
Authority
MX
Mexico
Prior art keywords
antigen
hpv
hepatitis
vaccine against
against hbv
Prior art date
Application number
MXPA02002483A
Other languages
English (en)
Inventor
Martine Anne Cecile Wettendorf
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of MXPA02002483A publication Critical patent/MXPA02002483A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se provee composiciones de vacuna novedosas que comprenden un antigeno viral de hepatitis B y un antigeno de VPH y, opcionalmente, ademas, uno o mas de los siguientes: un antigeno de VEB, un antigeno de hepatitis A o virus atenuado inactivado, un antigeno viral de Herpes simplex, un antigeno de VZV, un antigeno de HCMV, un antigeno de Toxoplasma gondii. Se formula las composiciones de vacuna con un adyuvante que es un estimulante preferencial de la respuesta de celula TH1, tal como 3D-MPL y Q521.
MXPA02002483A 1999-09-07 2000-09-06 Vacuna contra vhb y vph. MXPA02002483A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921147.6A GB9921147D0 (en) 1999-09-07 1999-09-07 Novel composition
PCT/EP2000/008728 WO2001017550A2 (en) 1999-09-07 2000-09-06 Vaccine against hbv and hpv

Publications (1)

Publication Number Publication Date
MXPA02002483A true MXPA02002483A (es) 2002-08-28

Family

ID=10860521

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02002483A MXPA02002483A (es) 1999-09-07 2000-09-06 Vacuna contra vhb y vph.

Country Status (29)

Country Link
US (2) US7371390B2 (es)
EP (2) EP1210112B1 (es)
JP (1) JP4694745B2 (es)
KR (1) KR100782637B1 (es)
CN (1) CN1171637C (es)
AR (1) AR025503A1 (es)
AT (2) ATE414533T1 (es)
AU (1) AU765245B2 (es)
BR (1) BR0014172A (es)
CA (1) CA2381047C (es)
CY (1) CY1106091T1 (es)
CZ (1) CZ2002842A3 (es)
DE (2) DE60027440T2 (es)
DK (1) DK1210112T3 (es)
ES (2) ES2261237T3 (es)
GB (1) GB9921147D0 (es)
GC (1) GC0000202A (es)
HK (1) HK1048436B (es)
HU (1) HUP0202826A3 (es)
IL (1) IL148455A0 (es)
MX (1) MXPA02002483A (es)
MY (1) MY134860A (es)
NO (1) NO20021115L (es)
NZ (1) NZ517622A (es)
PL (1) PL353923A1 (es)
PT (1) PT1210112E (es)
TR (1) TR200200608T2 (es)
WO (1) WO2001017550A2 (es)
ZA (1) ZA200201834B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
CN100406060C (zh) 1998-10-16 2008-07-30 史密丝克莱恩比彻姆生物有限公司 一种佐剂组合物
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
KR100525321B1 (ko) * 2002-12-13 2005-11-02 안웅식 파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
EP1758609B1 (en) * 2004-06-16 2012-10-03 GlaxoSmithKline Biologicals SA Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
PE20061300A1 (es) * 2005-03-23 2006-12-23 Glaxosmithkline Biolog Sa Composiciones inmunogenicas multivalentes que comprenden un antigeno de la gripe o preparacion antigenica en combinacion con un adyuvante de emulsion de aceite en agua
US20090181052A1 (en) * 2005-04-26 2009-07-16 Glaxosmithkline Biologicals Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP5739602B2 (ja) 2005-12-29 2015-06-24 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ブタの臨床症状の緩和のためのｐｃｖ２免疫原性組成物の使用
PL3320919T3 (pl) 2005-12-29 2020-11-30 Boehringer Ingelheim Animal Health USA Inc. Multiwalentne immunogenne kompozycje PCV2 i sposoby wytwarzania takich kompozycji
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2010001409A2 (en) * 2008-06-09 2010-01-07 Bharat Biotech International Limited Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
US10058605B2 (en) * 2012-05-09 2018-08-28 Bharat Biotech International Limited Vaccine combinations
KR101347288B1 (ko) * 2012-05-18 2014-01-06 안웅식 융합 폴리펩타이드 ｈｐｖ 항원을 이용한 ｈｐｖ 항체 스크리닝 키트

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563091A1 (en) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
NZ263538A (en) * 1993-03-23 1996-10-28 Smithkline Beecham Biolog Vaccine compositions of 3-o-deacylated monophosphoryl lipid a
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
EP2172216A3 (en) * 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
PL343429A1 (en) * 1998-03-09 2001-08-13 Smithkline Beecham Biolog Combined vaccine compositions
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition

Also Published As

Publication number Publication date
BR0014172A (pt) 2002-05-14
TR200200608T2 (tr) 2002-08-21
ES2261237T3 (es) 2006-11-16
HK1048436B (en) 2006-10-27
MY134860A (en) 2007-12-31
JP4694745B2 (ja) 2011-06-08
DE60040879D1 (de) 2009-01-02
GB9921147D0 (en) 1999-11-10
EP1210112A2 (en) 2002-06-05
KR100782637B1 (ko) 2007-12-06
JP2003508494A (ja) 2003-03-04
HUP0202826A3 (en) 2008-04-28
US20050123562A1 (en) 2005-06-09
AR025503A1 (es) 2002-11-27
KR20020027629A (ko) 2002-04-13
DK1210112T3 (da) 2006-08-14
PT1210112E (pt) 2006-08-31
CZ2002842A3 (cs) 2002-08-14
CY1106091T1 (el) 2011-06-08
WO2001017550A2 (en) 2001-03-15
EP1731167B1 (en) 2008-11-19
HUP0202826A2 (hu) 2002-12-28
AU7284800A (en) 2001-04-10
WO2001017550A3 (en) 2001-11-29
CA2381047C (en) 2010-08-03
PL353923A1 (en) 2003-12-15
CN1390136A (zh) 2003-01-08
ATE414533T1 (de) 2008-12-15
IL148455A0 (en) 2002-09-12
NO20021115L (no) 2002-04-30
DE60027440D1 (de) 2006-05-24
NO20021115D0 (no) 2002-03-06
HK1048436A1 (en) 2003-04-04
ES2314816T3 (es) 2009-03-16
GC0000202A (en) 2006-03-29
EP1210112B1 (en) 2006-04-19
NZ517622A (en) 2003-09-26
DE60027440T2 (de) 2006-10-19
US20080118527A1 (en) 2008-05-22
CA2381047A1 (en) 2001-03-15
EP1731167A1 (en) 2006-12-13
AU765245B2 (en) 2003-09-11
CN1171637C (zh) 2004-10-20
ZA200201834B (en) 2004-04-28
US7371390B2 (en) 2008-05-13
ATE323509T1 (de) 2006-05-15

Similar Documents

Publication Publication Date Title
MXPA02002483A (es) Vacuna contra vhb y vph.
MY135965A (en) Vaccine against hepatitis b and herpes simplex virus
WO2001017551A3 (en) Combined vaccine compositions
AU6616301A (en) Modification of hepatitis b core antigen
ES2070997T3 (es) Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
WO2000053729A3 (de) Virale partikel, die nach infektion durch humanes cytomegalovirus freigesetzt werden und ihre verwendung als impfstoff
CA2102918A1 (en) Genetic vaccine for immunodeficiency viruses
CA2370372A1 (en) Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
ZA92651B (en) Novel vaccine
MY134041A (en) Novel composition
IL137811A0 (en) Vaccines comprising interleukin-12 and herpes simplex viral antigen
EP1749885B8 (en) Infectious and attenuated bovine viral diarrhea virus vaccine
NZ516725A (en) Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
CA2116355A1 (en) Infectious bovine rhinotracheitis virus mutants and vaccines
BRPI0017420B8 (pt) composição de vacina, hpv 16 l1 e hpv 18 l1 vpl
WO2001083528A3 (en) Nucleic acid immunization
BR0014861A (pt) Partìculas virais com epìtopos internos exógenos
GB2409681A (en) Nucleic acid constructs for gene expression
ATE368116T1 (de) Schutzantigen des epstein-barr-virus
NZ242641A (en) Herpesvirus particles lacking a capsid and viral dna and viral preparations containing them
AR041249A2 (es) Una composicion de vacuna
AU4088299A (en) Novel post-transcriptional regulatory elements and uses thereof
WO2002078621A3 (en) Replication-competent recombinant virus and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration